Edition:
United States

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,890.15INR
23 Feb 2017
Change (% chg)

Rs-9.10 (-0.31%)
Prev Close
Rs2,899.25
Open
Rs2,920.00
Day's High
Rs2,920.00
Day's Low
Rs2,881.10
Volume
14,275
Avg. Vol
30,873
52-wk High
Rs3,689.00
52-wk Low
Rs2,803.50

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Ltd Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg
Monday, 28 Sep 2015 01:25am EDT 

Dr.Reddy's Laboratories Ltd:Says it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM Delayed-Release Capsules in the US market on September 25, 2015, following the approval by the United States Food & Drug Administration (USFDA).  Full Article

Dr.Reddy's Laboratories Ltd signs commercialization deal with Hatchtech
Monday, 14 Sep 2015 12:31am EDT 

Dr.Reddy's Laboratories Ltd:Announces signing of a commercialization deal with Hatchtech United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.Says the exclusive rights for this product are applicable for the territories of the.  Full Article

PanTheryx and Dr.Reddy's announce an agreement to market PanTheryx's Proprietary Nutritional Intervention for Pediatric Infectious Diarrhea
Tuesday, 8 Sep 2015 09:30pm EDT 

Dr.Reddy's Laboratories Ltd and PanTheryx Inc:Announces a multi-country supply and licensing agreement.The agreement grants the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention, DiaResQ (reg), for infectious diarrhea in India, Nepal, Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets.Says Dr. Reddy's will market the product in India and Nepal under the 'Reliqua' brand.  Full Article

Dr.Reddy's Laboratories Ltd voluntarily recalled a few batches of Amlodipine besylate and Atorvastatin from US market
Sunday, 6 Sep 2015 08:00pm EDT 

Dr.Reddy's Laboratories Ltd:Says has voluntarily recalled a few batches of amlodipine besylate and atorvastatin from the US market - Reuters.Says the impact of recall is not material.  Full Article

Dr.Reddy's Laboratories Ltd launches MINTOP PRO - Procapil Hair Therapy
Friday, 4 Sep 2015 07:13am EDT 

Dr.Reddy's Laboratories Ltd:Has announced its entry into the Hair Serum Market with the launch of MINTOP PRO - Procapil Hair Therapy.  Full Article

Dr.Reddy's Laboratories Ltd announces the Launch of PRAMIPEXOLE Dihydrochloride Extended-Release Tablets
Wednesday, 12 Aug 2015 07:58am EDT 

Dr.Reddy's Laboratories Ltd:Announces the Launch of PRAMIPEXOLE Dihydrochloride Extended-Release Tablets 0.375 mg, 0.75 mg, 1.5 mg, and 4.5 mg a therapeutic equivalent generic version of MIRAPEXER, Extended-Release Tablets in the US market on Aug. 11.  Full Article

Dr.Reddy's Laboratories Ltd announces strategic collaboration with Amgen in India
Thursday, 6 Aug 2015 12:33am EDT 

Dr.Reddy's Laboratories Ltd:Announces strategic collaboration with Amgen in India.Eneters into a strategic collaboration to market and distribute three Amgen medicines in India in the areas of oncology and cardiology.  Full Article

Dr.Reddy's Laboratories Ltd recalls anti-seizure drugs from US market - DION Global (India)
Sunday, 28 Jun 2015 08:00pm EDT 

Dr.Reddy's Laboratories Ltd:Says has initiated a voluntary recall of some drugs used to treat seizure and hypertension from the US market, reported PTI - DION Global (India).Says started recalling Divalproex Sodium extended-release tablets, USP, 250 mg of 100 count (7,479 units) and 500 count bottles (2,544) units on the ground of failed dissolution specifications, exceeded specification at the 9-hour time point.Says recall of these tablets is being made under class III classification.  Full Article

Dr.Reddy's Laboratories Ltd recommends final dividend
Tuesday, 12 May 2015 03:46am EDT 

Dr.Reddy's Laboratories Ltd:Recommends final dividend of 20 Indian rupees (400 pct) per equity share of 5 Indian rupees face value, for FY 2014-15.  Full Article

Dr.Reddy's Laboratories Ltd files three new drug applications with USFDA - PTI
Tuesday, 7 Apr 2015 10:49pm EDT 

Dr.Reddy's Laboratories Ltd:Has filed three new drug applications (NDAs), aimed to be used in the treatments of psoriasis, rosacea, migraine, with the US health regulator - PTI.The company and its subsidiary, Promius Pharma LLC have filed three new drug applications with the US Food and Drug Administration (USFDA).The three NDAs - DFD-01, DFD-09, and DFN-11 is focused on developing and commercialising therapies in dermatology and neurology.Upon approval, the products will be commercialised by Promius Pharma.  Full Article

More From Around the Web

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017